Results 71 to 80 of about 17,302 (216)
Summary Complete remission (CR) rates for patients with acute myeloid leukaemia (AML) treated with intensive chemotherapy (IC) have increasingly improved. Yet, relapse remains a concern with a dismal prognosis. In this report, results are presented of a retrospective analysis comparing salvage therapy based on intermediate (I) or high (H)‐dose ...
Pierre‐Yves Dumas +22 more
wiley +1 more source
A phase IIa study of the anti‐PD‐L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL‐T trial
The AVAIL‐T study, the first evaluation of programmed death ligand 1 (PD‐L1) blockade in relapsed/refractory peripheral T‐cell lymphomas (PTCL), demonstrated limited single agent activity with durable responses seen in a minority. Circulating tumour DNA revealed distinct mutational dynamics and mass cytometry identified perturbed T‐cell subsets ...
Matthew J. Ahearne +28 more
wiley +1 more source
BackgroundAzacitidine is used to treat myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It acts as a cytosine analog and DNA methyltransferase inhibitor, inducing DNA hypomethylation to reverse epigenetic modifications and restore normal ...
Zhaorui Wang +5 more
doaj +1 more source
Azacitidine, an inhibitor of DNA methylation, shows therapeutic effects against several malignancies by inducing apoptosis and inhibiting tumor cell proliferation.
Ya-Chuan Chang +5 more
core +1 more source
Summary Lack of response or delayed response to therapy are major challenges in the use of DNA‐hypomethylating agents (HMA) in patients with acute myeloid leukaemia (AML). Fetal haemoglobin (HbF) is a potential biomarker for response to HMA treatment but has only been studied in small single‐centre studies.
Julia Stomper +27 more
wiley +1 more source
Azacitidine/venetoclax is an active regimen in patients with newly diagnosed AML. However, primary or secondary resistance to azacitidine/venetoclax is an area of unmet need and overexpression of MCL-1 is suggested to be a potential resistance mechanism.
Guru Subramanian Guru Murthy +17 more
doaj +1 more source
Combined azacitidine and romidepsin enhances cytotoxicity in azacitidine-sensitive but not in azacitidine-resistant multiple myeloma cell lines. [PDF]
In hematopoietic tumor cells, aberrant epigenetic alterations of hypermethylation or histone deacetylation are usually observed. In multiple myeloma (MM), histone deacetylase inhibitors (HDIs) have proven anti-tumor activity, whereas the effects of DNA ...
Ozawa, Keiya +2 more
core
Summary The leukaemia in pregnancy study was a multicentre retrospective study of pregnancy outcomes of women with concurrent (CAL) or previous (PAL) acute leukaemia. Cases were identified from eight hospitals. Of 39 screened cases, 12 CAL and 21 PAL cases were described, with one belonging to both groups.
Lukas Pitel +14 more
wiley +1 more source
Demethylating Agents in the Treatment of Cancer
Gene silencing resulting from aberrant DNA methylation can lead to tumorigenesis. Therefore, drugs that inhibit or interfere with DNA methylation have been used to reactivate and induce silenced gene re-expression in malignancies.
Paul M. Howell, Jr. +2 more
doaj +1 more source
Ligand atom energies and contribution of the iNOS residues/molecules with azacitidine.
Ligand atom energies and contribution of the iNOS residues/molecules with azacitidine.
Mahdieh Lashkarizadeh (16955395) +9 more
core +1 more source

